Tags

Type your tag names separated by a space and hit enter

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Mov Disord. 1998 Sep; 13(5):798-802.MD

Abstract

The antidyskinetic potential of the glutamate NMDA receptor channel blocker amantadine was evaluated in four levodopa-primed parkinsonian monkeys using two different regimens (1.25 or 2.5 mg/kg administered subcutaneously twice daily for 3-6 days). When administered with a relatively low dose of levodopa, amantadine produced a near-total suppression of choreiform dyskinesias and a substantial reduction in dystonic dyskinesias at the expense of a significant reduction in antiparkinsonian response. With a high dose of levodopa, amantadine had a smaller but still significant effect on dyskinesias without altering the antiparkinsonian response. These results lend support to the view that glutamate receptor-mediated mechanisms contribute to levodopa-induced dyskinesias. They also suggest that amantadine could alleviate such complications in parkinsonian patients, especially with careful dose optimization.

Authors+Show Affiliations

Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20892-1406, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9756148

Citation

Blanchet, P J., et al. "Amantadine Reduces Levodopa-induced Dyskinesias in Parkinsonian Monkeys." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 13, no. 5, 1998, pp. 798-802.
Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord. 1998;13(5):798-802.
Blanchet, P. J., Konitsiotis, S., & Chase, T. N. (1998). Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Movement Disorders : Official Journal of the Movement Disorder Society, 13(5), 798-802.
Blanchet PJ, Konitsiotis S, Chase TN. Amantadine Reduces Levodopa-induced Dyskinesias in Parkinsonian Monkeys. Mov Disord. 1998;13(5):798-802. PubMed PMID: 9756148.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. AU - Blanchet,P J, AU - Konitsiotis,S, AU - Chase,T N, PY - 1998/10/2/pubmed PY - 1998/10/2/medline PY - 1998/10/2/entrez SP - 798 EP - 802 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 13 IS - 5 N2 - The antidyskinetic potential of the glutamate NMDA receptor channel blocker amantadine was evaluated in four levodopa-primed parkinsonian monkeys using two different regimens (1.25 or 2.5 mg/kg administered subcutaneously twice daily for 3-6 days). When administered with a relatively low dose of levodopa, amantadine produced a near-total suppression of choreiform dyskinesias and a substantial reduction in dystonic dyskinesias at the expense of a significant reduction in antiparkinsonian response. With a high dose of levodopa, amantadine had a smaller but still significant effect on dyskinesias without altering the antiparkinsonian response. These results lend support to the view that glutamate receptor-mediated mechanisms contribute to levodopa-induced dyskinesias. They also suggest that amantadine could alleviate such complications in parkinsonian patients, especially with careful dose optimization. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/9756148/Amantadine_reduces_levodopa_induced_dyskinesias_in_parkinsonian_monkeys_ L2 - https://doi.org/10.1002/mds.870130507 DB - PRIME DP - Unbound Medicine ER -